Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

BACKGROUND: Previous trials showed that antiangiogenesis or anti-programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) monotherapy only showed marginal effect in triple-negative breast cancer (TNBC). Preclinical studies demonstrated that antiangiogenic therapy could sensitize breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jieqiong, Liu, Qiang, Li, Ying, Li, Qian, Su, Fengxi, Yao, Herui, Su, Shicheng, Wang, Quanren, Jin, Liang, Wang, Ying, Lau, Wan Yee, Jiang, Zefei, Song, Erwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252975/
https://www.ncbi.nlm.nih.gov/pubmed/32448804
http://dx.doi.org/10.1136/jitc-2020-000696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252975/
https://www.ncbi.nlm.nih.gov/pubmed/32448804
http://dx.doi.org/10.1136/jitc-2020-000696

Ejemplares similares